Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - May 15, 2024 - "UPCOMING EXPECTED EVENTS AND MILESTONES:...(i) FDA granted ReSPECT-LM Type C meeting for a multi-dose Phase 1 dose escalation study, scheduled for June 10, 2024; (ii) Anticipate FDA feedback in second half 2024 for ReSPECT-PBC investigational new drug application (IND) for pediatric ependymoma and high-grade glioma, with the aim of attaining IND approval."
FDA event • Ependymoma • Glioma
|